NCT01882543 - Efficacy and Safety of AQX-1125 in IC/BPS | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 30, 2013

Primary Completion Date

June 30, 2015

Study Completion Date

June 30, 2015

Conditions

Interstitial CystitisBladder Pain Syndrome

Interventions

DRUG

AQX-1125

Synthetic SHIP1 activator

DRUG

Placebo

Double blind placebo capsule

Trial Locations (29)

11530

AQX/CMX site, Garden City

27103

AQX/CMX Site, Winston-Salem

32801

AQX/CMX site, Orlando

35209

AQX/CMX site, Homewood

43615

AQX/CMX site, Toledo

48084

AQX/CMX site, Troy

71106

AQX/CMX site, Shreveport

75115

AQX/CMX site, DeSoto

80211

AQX/CMX site, Denver

91741

AQX/CMX site, Glendora

92123

AQX/CMX site, San Diego

06032

AQX/CMX site, Farmington

T2V1P9

AQX/CMX site, Calgary

Unknown

AQX/CMX site, Kelowna

AQX/CMX site, Victoria

AQX/CMX site, Barrie

AQX/CMX site, Brampton

AQX/CMX site, Brantford

AQX/CMX site, Burlington

AQX/CMX site, Kingston

AQX/CMX site, Kitchener

AQX/CMX site, Oakville

AQX/CMX site, Toronto

Dr Lesley Carr, Toronto

AQX/CMX site, Granby

AQX/CMX site, Montreal

AQX/CMX site, Sherbrooke

V6Z1Y6

AQX/CMX Site, Vancouver

B3H2Y9

AQX/CMX site, Halifax